Skip to main content

View full-text article in PMC

. 2022 May 17;27(9):e748–e754. doi: 10.1093/oncolo/oyac092

Table 3.

Skeletal muscle performance metrics.

Spectroscopy variable	Control (n = 16)	Patients (n = 34)
Spectroscopy variable	Control (n = 16)	Pre-chemotherapy	Mid-chemotherapy	End-chemotherapy	One year
Incremental maximal test plantar flexion test peak power output (W)	15.7 (3.1)	14.5 (3.5)	14.7 (3.8)	14.3 (3.8)	14.6 (3.6)
Submaximal 4-minute steady-state plantarflexion test power output (W)	10.0 (1.9)	8.9 (2.0)	9.1 (2.1)	8.9 (2.3)	9.2 (2.2)
Plantarflexion exercise efficiency (power output/VO₂ reserve, W/mL/minute)	0.25 (0.08)	0.24 (0.07)	0.22 (0.05)	0.21 (0.07)^a ^b	0.23 (0.07)
Cycle ergometer pulmonary VO₂peak (mL/kg/minute)	29.5 (7.7)	27.5 (7.1)	n/a	25.1 (6.7)^a	26.8 (7.0)
Cycle ergometer pulmonary VO₂peak (L/minute)	2.13 (0.41)	1.97 (0.49)	n/a	1.82 (0.47)^a	1.94 (0.44)
Leg press 1-repetition maximum (kg)	n/a	86.2 (38.4)	n/a	77.7 (30.9)^a	86.0 (29.3)

Different from pre-chemotherapy (P ≤ .05).

Different from mid-chemotherapy (P ≤ .05).

n/a = not collected.